Intelligence Feed event · Macro · 2026-10-01

    Survodutide Phase III Trial Achieves 13.1% Weight Loss in T2D Obesity

    Question

    Survodutide Phase III Trial Achieves 13.1% Weight Loss in T2D Obesity

    Direct answer

    Boehringer Ingelheim and development partner Zealand Pharma released top-line data from the 76-week SYNCHRONIZE-2 Phase III study. The dual glucagon/GLP-1 agonist reached 13.1% mean body weight reduction in patients with both obesity and type 2 diabetes, providing clinical validation for the dual mechanism ahead of commercial filings.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-01
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Survodutide Phase III Trial Achieves 13.1% Weight Loss in T2D Obesity”, revision 1, evidence through 2026-10-01. https://marketontology.com/market-events/2026-10-01/survodutide-phase-iii-trial-achieves-13-1-weight-loss-in-t2d-obesity-e9001a

    MACRO
    Survodutide Phase III Trial Achieves 13.1% Weight Loss in T2D Obesity
    Boehringer Ingelheim and development partner Zealand Pharma released top-line data from the 76-week SYNCHRONIZE-2 Phase III study. The dual glucagon/GLP-1 agonist reached 13.1% mean body weight reduction in patients with both obesity and type 2 diabetes, providing clinical validation for the dual mechanism ahead of commercial filings.
    ZLDPY
    Impact
    74
    OCT 1
    SIG
    90%
    ZLDPY
    Survodutide Phase III Trial Achieves 13.1% Weight Loss in T2D Obesity
    Boehringer Ingelheim and development partner Zealand Pharma released top-line data from the 76-week SYNCHRONIZE-2 Phase III study. The dual glucagon/GLP-1 agonist reached 13.1% mean body weight reduction in patients with both obesity and type 2 diabetes, providing clinical validation for the dual mechanism ahead of commercial filings.
    → Statistically significant Phase III efficacy advances survodutide toward regulatory submission, driving valuation revisions for licensing partner Zealand Pharma.
    Impact
    Boehringer Ingelheim and development partner Zealand Pharma released top-line data from the 76-week SYNCHRONIZE-2 Phase III study. The dual glucagon/GLP-1 agonist reached 13.1% mean body weight reduction in patients with both obesity and type 2 diabetes, providing clinical validation for the dual mechanism ahead of commercial filings.
    Affected
    ZLDPY
    Transmission
    Statistically significant Phase III efficacy advances survodutide toward regulatory submission, driving valuation revisions for licensing partner Zealand Pharma.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    ZLDPYmilestone and future royalty cash flow accretion on regulatory filing progressUp1-4wSource explicitly names Phase III trial success for Zealand Pharma's licensed asset survodutide.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month